Infection

, Volume 41, Issue 1, pp 199–202

Could anti-HCV treatment prevent recurrence of hepatocellular carcinoma in HIV-infected patients? Two case reports

Authors

  • G. Cenderello
    • Department of Infectious DiseasesEO Ospedali Galliera
    • Department of Infectious DiseasesEO Ospedali Galliera
  • G. Cassola
    • Department of Infectious DiseasesEO Ospedali Galliera
  • A. Torresin
    • Department of Infectious DiseasesEO Ospedali Galliera
Brief Report

DOI: 10.1007/s15010-012-0353-3

Cite this article as:
Cenderello, G., Pontali, E., Cassola, G. et al. Infection (2013) 41: 199. doi:10.1007/s15010-012-0353-3

Abstract

Highly active antiretroviral therapy (HAART) has proven long-term efficacy in human immunodeficiency virus (HIV) infection. Combination therapy with pegylated interferon and ribavirin has become the standard of care in patients with both hepatitis C virus (HCV) chronic hepatitis and HIV/HCV co-infection. Data on the safety and efficacy of combination therapy in chronic hepatitis C patients with hepatocellular carcinoma (HCC) is scarce and even more so in HIV/HCV co-infected subjects. We report the successful administration of both HAART and anti-HCV therapies in two HIV/HCV co-infected patients after HCC eradication. These encouraging results might argue for the feasibility of an aggressive approach in the management of co-infected patients with HCC.

Copyright information

© Springer-Verlag Berlin Heidelberg 2012